Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navtemadlin in Recurrent and Newly Diagnosed Glioblastoma
NCT03107780Phase 1Terminated
- Sponsor
- National Cancer Institute
- Start
- Jul 2018
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of navtemadlin in glioblastoma (GBM), sponsored by National Cancer Institute. Primary endpoints: Pharmacokinetics parameters with target inter-tumor drug concentration up to 5 years and Maximum Tolerated Dose up to 16 weeks. Started Jul 2018; status: terminated.
02
Drugs
navtemadlin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03107780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03107780.